Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study

Cristina Domingo, Juliane Fraissinet, Patrick O Ansah, Corey Kelly, Niranjan Bhat, Samba O Sow, José E Mejía, Cristina Domingo, Juliane Fraissinet, Patrick O Ansah, Corey Kelly, Niranjan Bhat, Samba O Sow, José E Mejía

Abstract

Background: A single dose of vaccine against yellow fever is routinely administered to infants aged 9-12 months under the Expanded Programme on Immunization, but the long-term outcome of vaccination in this age group is unknown. We aimed to evaluate the long-term persistence of neutralising antibodies to yellow fever virus following routine vaccination in infancy.

Methods: We did a longitudinal cohort study, using a microneutralisation assay to measure protective antibodies against yellow fever in Malian and Ghanaian children vaccinated around age 9 months and followed up for 4·5 years (Mali), or 2·3 and 6·0 years (Ghana). Healthy children with available day-0 sera, a complete follow-up history, and no record of yellow fever revaccination were included; children seropositive for yellow fever at baseline were excluded. We standardised antibody concentrations with reference to the yellow fever WHO International Standard.

Findings: We included 587 Malian and 436 Ghanaian children vaccinated between June 5, 2009, and Dec 26, 2012. In the Malian group, 296 (50·4%, 95% CI 46·4-54·5) were seropositive (antibody concentration ≥0·5 IU/mL) 4·5 years after vaccination. Among the Ghanaian children, 121 (27·8%, 23·5-32·0) were seropositive after 2·3 years. These results show a large decrease from the proportions of seropositive infants 28 days after vaccination, 96·7% in Mali and 72·7% in Ghana, reported by a previous study of both study populations. The number of seropositive children increased to 188 (43·1%, 95% CI 38·5-47·8) in the Ghanaian group 6·0 years after vaccination, but this result might be confounded by unrecorded revaccination or natural infection with wild yellow fever virus during a 2011-12 outbreak in northern Ghana.

Interpretation: Rapid waning of immunity during the early years after vaccination of 9-month-old infants argues for a revision of the single-dose recommendation for this target population in endemic countries. The short duration of immunity in many vaccinees suggests that booster vaccination is necessary to meet the 80% population immunity threshold for prevention of yellow fever outbreaks.

Funding: Wellcome Trust.

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Forest plots of the prevalence of seropositive children Seropositive participants at the antibody concentration threshold of 0·5 IU/mL or more are shown at the top of the figure, and seropositive and borderline study participants are presented at the bottom as a merged category including all participants with a measurable titre. p values test the differences of proportions between groups.
Figure 2
Figure 2
Reverse cumulative distribution plots of neutralising antibody values (A) Raw titres in the plaque reduction seroneutralisation assay for the full study groups. (B) Standardised antibody concentrations for broadly seropositive children (ie, seropositive and borderline study participants). The dotted line denotes the threshold for strict seropositivity at 0·5 IU/ml.
Figure 3
Figure 3
Evolution of the Ghanaian cohort Flow of study participants from a year-2·3 to a year-6·0 antibody concentration stratum. The thickness of the nodes (initial and final) and links between them are proportional to the number of participants as shown on the figure.

References

    1. WHO . Yellow fever fact sheet. World Health Organization; Geneva: 2019.
    1. Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. 2015;64:160–173.
    1. Garske T, Van Kerkhove MD, Yactayo S. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11:e1001638.
    1. Shearer FM, Moyes CL, Pigott DM. Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. Lancet Infect Dis. 2017;17:1209–1217.
    1. WHO Vaccines and vaccination against yellow fever: WHO position paper, June 2013—recommendations. Vaccine. 2015;33:76–77.
    1. Amanna IJ, Slifka MK. Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Rev Vaccines. 2016;15:1519–1533.
    1. Collaborative Group for Studies of Yellow Fever Vaccination A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz. 2015;110:771–780.
    1. Hepburn MJ, Kortepeter MG, Pittman PR. Neutralizing antibody response to booster vaccination with the 17D yellow fever vaccine. Vaccine. 2006;24:2843–2849.
    1. Monath TP, Cetron MS, McCarthy K. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005;1:207–214.
    1. de Menezes Martins R, Maia MLS, de Lima SMB. Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study. Vaccine. 2018;36:4112–4117.
    1. Wieten RW, Goorhuis A, Jonker EFF. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients. J Infect. 2016;72:713–722.
    1. Campi-Azevedo AC, de Almeida Estevam P, Coelho-Dos-Reis JG. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis. 2014;14:391.
    1. Lydersen S, Fagerland MW, Laake P. Recommended tests for association in 2×2 tables. Stat Med. 2009;28:1159–1175.
    1. Ruxton GD, Neuhäuser M. Improving the reporting of P-values generated by randomization methods. Methods Ecol Evol. 2013;4:1033–1036.
    1. Chowdhury Roy, Meier P C, Laraway H. Immunogenicity of yellow fever vaccine coadministered with MenAfriVac in healthy infants in Ghana and Mali. Clin Infect Dis. 2015;61(suppl 5):S586–S593.
    1. WHO . International health regulations (2005) 3rd. World Health Organization; Geneva: 2016.
    1. Gotuzzo E, Yactayo S, Cordova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434–444.
    1. Staples JE, Bocchini JA, Jr, Rubin L, Fischer M. Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:647–650.
    1. Estofolete CF, Nogueira ML. Is a dose of 17D vaccine in the current context of yellow fever enough? Braz J Microbiol. 2018;49:683–684.
    1. Vasconcelos PF. Single shot of 17D vaccine may not confer life-long protection against yellow fever. Mem Inst Oswaldo Cruz. 2018;113:135–137.
    1. Grobusch MP, van Aalst M, Goorhuis A. Yellow fever vaccination—once in a lifetime? Travel Med Infect Dis. 2017;15:1–2.
    1. Patel D, Simons H. Yellow fever vaccination: is one dose always enough? Travel Med Infect Dis. 2013;11:266–273.
    1. CDC . Grading of recommendations, assessment, development, and evaluation (GRADE) for yellow fever vaccine booster doses. Centers for Disease Control and Prevention; 2015. June 3.
    1. WHO Eliminate yellow fever epidemics (EYE): a global strategy, 2017–2026. Wkly Epidemiol Rec. 2017;92:193–204.
    1. Watson AM, Lam LK, Klimstra WB, Ryman KD. The 17D-204 vaccine strain-induced protection against virulent yellow fever virus is mediated by humoral immunity and CD4+ but not CD8+ T cells. PLoS Pathog. 2016;12:e1005786.
    1. Campi-Azevedo AC, Costa-Pereira C, Antonelli LR. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vacc Immunother. 2016;12:491–502.
    1. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59:895–900.
    1. Goujon C, Gougeon ML, Tondeur L. CHRONOVAC VOYAGEUR: a study of the immune response to yellow fever vaccine among infants previously immunized against measles. Vaccine. 2017;35:6166–6171.
    1. Nascimento Silva JR, Camacho LA, Siqueira MM. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29:6327–6334.
    1. Michel R, Berger F, Ravelonarivo J. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines? Vaccine. 2015;33:2301–2306.
    1. Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg. 1999;60:1045–1050.
    1. Monath TP, Nichols R, Archambault WT. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002;66:533–541.
    1. Moore SE, Collinson AC, Fulford AJ. Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan. Trop Med Int Health. 2006;11:1529–1541.
    1. Muyanja E, Ssemaganda A, Ngauv P. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest. 2014;124:3147–3158.
    1. IFRC . DREF final report. Ghana: Yellow fever outbreak. DREF operation n? MDRGH005. International Federation of Red Cross and Red Crescent Societies; 2012.
    1. Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003;60:343–395.
    1. Kongsgaard M, Bassi MR, Rasmussen M. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination. Sci Rep. 2017;7:662.
    1. Lhuillier M, Mazzariol MJ, Zadi S. Study of combined vaccination against yellow fever and measles in infants from six to nine months. J Biol Stand. 1989;17:9–15.
    1. Stefano I, Sato HK, Pannuti CS. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. Vaccine. 1999;17:1042–1046.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren